Serum Kisspeptin Levels in Infertile Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-30

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study population is comprise of 90 women those age varies between 18-38 year-old. The first group will comprise of 30 women with polycystic ovaries or anovulatory cycles, the second group will comprise of 30 women with diagnosis of unexplained infertility and the third group will comprise of 30 women those partners with male subfertility. A 2 cc blood sample for Kisspeptin analysis will be drawn from the antecubital vein from each participants. The patients will receive 50 mg clomiphene citrate at the fifth day of the menstrual period and follicular development will be measured with serial ultrasound follow up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Cohort Study on the Serum Kisspeptin Levels Throughout Pregnancy in PCOS

NCT06545994

Polycystic Ovary Syndrome Pregnancy Complications

RECRUITING

Dampening the Reproductive Axis With Continuous Kisspeptin

NCT05971849

Reproductive Disorder PCOS Polycystic Ovary Syndrome

COMPLETED PHASE1

The Effect of the Ovarian Reserve on the Recurrent Pregnancy Loss

NCT03009370

Ovarian Reserve Miscarriage, Recurrent

UNKNOWN

Role of Nesfatin-1 and Nicotinamide in Infertile Women With Polycystic Ovary Syndrome

NCT03870035

PCOS

UNKNOWN

Thiol/Disulphide Homeostasis in Unexplained Infertility

NCT05628766

Oxidative Stress Infertility Antioxidative Stress

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population is comprise of 90 women those age varies between 18-38 year-old with wish of baby for at least one year despite of unprotected sexual intercourse, patent tubes confirmed in hysterosalpingography , follicle stimulating hormone levels \<12 IU. The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles, the second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility and the third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility \<%32 and Kruger morphology \<4%. A 2 cc blood sample for Kisspeptin analysis will be drawn from the antecubital vein from each participants and centrifuged and sera will be kept in -80 C till recruitment has been completed. Kisspeptin, E2, Progesterone, anti-mullerian hormone levels will be measured with ELISA method. The patients will receive 50 mg clomiphene citrate at the fifth day of the menstrual period and follicular development will be measured with serial ultrasound follow up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility, Female Unexplained Infertility Anovulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.

Blood sample

* ages other than 18-38 year-old with wish of baby for least than one year despite of unprotected sexual intercourse
* obstructed tubes confirmed in hysterosalpingography
* follicle stimulating hormone levels \>12 IU
* history thyroid disease
* increased prolactin levels
* history of chemo/radiation therapy

Minimum Eligible Age

18 Years

Maximum Eligible Age

38 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No